New hope for kids with hard-to-treat cancers? neratinib trial underway

NCT ID NCT02932280

First seen Jan 09, 2026 · Last updated May 01, 2026 · Updated 20 times

Summary

This study tests the safety of a drug called neratinib in children and teens with solid tumors, brain tumors, lymphoma, or leukemia that have returned or not responded to standard treatments. The goal is to find the best dose and see what side effects occur. The study involves 14 participants and is no longer recruiting new patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alberta Children'S Hospital

    Calgary, Alberta, T3B 6A8, Canada

  • Arkansas Children's Hospital

    Little Rock, Arkansas, 72206, United States

  • Arnold Palmer Hospital for Children

    Orlando, Florida, 32806, United States

  • Huntsman Cancer Institue

    Salt Lake City, Utah, 84113, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Pennsylvania State Hershey Children's Hospital

    Hershey, Pennsylvania, 17033, United States

  • Phoenix Children'S Hospital

    Phoenix, Arizona, 85016, United States

  • Stanford University School of Medicine and Stanford Cancer Institute

    Palo Alto, California, 94304, United States

  • University of Texas

    San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.